Aspyra (OTCMKTS:APYI – Get Free Report) and Privia Health Group (NASDAQ:PRVA – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.
Volatility & Risk
Aspyra has a beta of 2.14, suggesting that its share price is 114% more volatile than the S&P 500. Comparatively, Privia Health Group has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.
Valuation & Earnings
This table compares Aspyra and Privia Health Group”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aspyra | N/A | N/A | N/A | N/A | N/A |
| Privia Health Group | $1.74 billion | 1.56 | $14.39 million | $0.13 | 169.15 |
Privia Health Group has higher revenue and earnings than Aspyra.
Insider and Institutional Ownership
94.5% of Privia Health Group shares are held by institutional investors. 23.9% of Aspyra shares are held by company insiders. Comparatively, 10.7% of Privia Health Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Aspyra and Privia Health Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aspyra | N/A | N/A | N/A |
| Privia Health Group | 0.89% | 2.52% | 1.47% |
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Aspyra and Privia Health Group, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aspyra | 0 | 0 | 0 | 0 | 0.00 |
| Privia Health Group | 0 | 3 | 13 | 0 | 2.81 |
Privia Health Group has a consensus target price of $30.50, indicating a potential upside of 38.70%. Given Privia Health Group’s stronger consensus rating and higher probable upside, analysts plainly believe Privia Health Group is more favorable than Aspyra.
Summary
Privia Health Group beats Aspyra on 8 of the 10 factors compared between the two stocks.
About Aspyra
Aspyra Inc. provides health care products and services for the laboratory and imaging marketplaces. It offers engineered workflow solutions that include software, interfaces, hardware, and professional services to various markets comprising specialty labs, reference labs, clinics, hospitals, imaging centers, and orthopedic practices. The company was formerly known as Creative Computer Applications Inc. and changed its name to Aspyra Inc. in November 2005. Aspyra Inc. was founded in 1978 and is headquartered in Jacksonville, Florida.
About Privia Health Group
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings. It offers technology and population health tools to enhance independent providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; accountable care organization, which engage patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect with new patient populations and create custom contracts. The company was founded in 2007 and is headquartered in Arlington, Virginia.
Receive News & Ratings for Aspyra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspyra and related companies with MarketBeat.com's FREE daily email newsletter.
